Who Paid My Doc
Christopher French
Cytopathology Boston, MA Medical Doctor
NPI 1285690404 CMS profile 741224
75 Francis Street Amory 3, Brigham And Womens Hospital Department Of Pathology, Boston, MA 02115
General payments
$19,612
Research payments
$91,533
Ownership & investment interest
$0
Research they led as principal investigator
$35,483
Through program year 2020, Christopher French of Boston, MA is reported in the CMS Open Payments database as having received $19,612 across 11 general payments and $91,533 in research payments paid to them. Separately, studies naming them as principal investigator received $35,483 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cytopathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $2,414 | 2 | |
| 2020 | Research | $91,533 | 2 | |
| 2019 | General | $17,199 | 9 |
Beside peers
- Christopher French
- Cytopathology median
- Middle half of Cytopathology
- National median
In program year 2025, general payments to Christopher French were reported at $0. Among 60 Cytopathology profiles paid that year, the median was $56 and the middle half received between $24 and $145.
Show as a table
| Year | Christopher French | Cytopathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $17,199 | $52 | $21–$145 | $163 |
| 2020 | $2,414 | $47 | $22–$379 | $114 |
| 2021 | $0 | $28 | $18–$101 | $132 |
| 2022 | $0 | $86 | $24–$153 | $149 |
| 2023 | $0 | $51 | $23–$125 | $160 |
| 2024 | $0 | $36 | $20–$204 | $164 |
| 2025 | $0 | $56 | $24–$145 | $169 |
Breakdown
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$18,495
Medicare patients
292
Services billed
600
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 48% | |
| Arthritis | 45% | |
| Chronic kidney disease | 32% | |
| Ischemic heart disease | 29% | |
| Diabetes | 28% | |
| Depression | 27% | |
| Atrial fibrillation | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cytopathology in Massachusetts
Related records
Cytopathology in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Cytopathology
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.